|
End-of-day quote
Taipei Exchange
06/05/2024
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 13/08 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: UBI Pharma Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 944.2 | 7,796 | 5,567 | 4,095 | 1,683 | 1,683 |
| Change | - | 725.68% | -28.59% | -26.44% | -58.9% | 0% |
| Enterprise Value (EV) 1 | 1,731 | 8,268 | 5,686 | 4,255 | 1,930 | 1,972 |
| Change | - | 377.54% | -31.22% | -25.17% | -54.66% | 2.2% |
| P/E | -12x | 327x | 116x | 5,009x | -9.63x | -5.68x |
| PBR | 2.06x | 8.65x | 4.98x | 3.5x | 1.69x | 2.41x |
| PEG | - | -3x | 1.3x | -50.9x | 0x | -0.1x |
| Capitalization / Revenue | 1.98x | 12.1x | 8.78x | 6.31x | 3.12x | 3.27x |
| EV / Revenue | 3.63x | 12.8x | 8.97x | 6.56x | 3.58x | 3.83x |
| EV / EBITDA | -15.7x | 104x | 75.9x | 76.2x | -43.9x | -22.9x |
| EV / EBIT | -11.3x | 179x | 152x | 780x | -17x | -12.2x |
| EV / FCF | 13.7x | -68.5x | 204x | -33.2x | -32.4x | 93x |
| FCF Yield | 7.31% | -1.46% | 0.49% | -3.01% | -3.09% | 1.07% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.83 | 0.218 | 0.4134 | 0.006918 | -1.48 | -2.51 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 477.6 | 644.3 | 633.8 | 648.6 | 538.8 | 514.4 |
| EBITDA 1 | -109.9 | 79.33 | 74.9 | 55.86 | -43.91 | -85.96 |
| EBIT 1 | -153.8 | 46.11 | 37.32 | 5.453 | -113.4 | -161.7 |
| Net income 1 | -74.22 | 22.36 | 47.21 | 0.803 | -174.5 | -296.3 |
| Net Debt 1 | 787.2 | 472.1 | 119 | 160 | 246.4 | 288.9 |
| Reference price 2 | 9.95 | 71.22 | 48.12 | 34.65 | 14.25 | 14.25 |
| Nbr of stocks (in thousands) | 94,935 | 1,09,464 | 1,15,696 | 1,18,190 | 1,18,120 | 1,18,120 |
| Announcement Date | 19/04/21 | 29/04/22 | 21/04/23 | 18/04/24 | 30/04/25 | 27/04/26 |
1TWD in Million2TWD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 5.13Cr | |
| 41.32x | 13.98x | 29.71x | 0.48% | 1,25800Cr | |
| 41.29x | 6.93x | 19.48x | 1.89% | 68TCr | |
| 37.78x | 8.57x | 17.7x | 2.35% | 52TCr | |
| 21.56x | 5.23x | 13.1x | 2.5% | 39TCr | |
| 105.59x | 6.02x | 25.64x | 2.28% | 37TCr | |
| 23.81x | 5.93x | 14.32x | 2.69% | 31TCr | |
| 24.64x | 4.94x | 13.88x | 1.76% | 29TCr | |
| 24x | 7.37x | 13.68x | 2.17% | 25TCr | |
| -39.75x | 7.37x | 46.38x | 1.95% | 21TCr | |
| Average | 31.14x | 7.37x | 21.54x | 2.01% | 43TCr | |
| Weighted average by Cap. | 37.19x | 8.81x | 22.45x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6562 Stock
- Valuation UBI Pharma Inc.
Select your edition
All financial news and data tailored to specific country editions
